Introduction
Dopamine (DA) receptors are members of the G-protein-coupled receptor family, which consists of five subtypes, namely, the D 1 -like receptors, D 1 and D 5 , and the D 2 -like receptors, D 2 , D 3 and D 4 . In response to agonist binding, the DA receptors activate respective G-proteins, resulting in subsequent activation of second messenger systems. The activated DA receptor subsequently undergoes desensitization, internalization and resensitization [1, 2] . Agonist-mediated internalization is believed to be an important mechanism for discharging the bound receptors and making receptor sites available again on the surface of the cell membrane. Thus, studying receptor trafficking and its regulatory mechanisms is critical for understanding receptor function and regulation. It has been reported that, in response to stimulation, perisynaptic DA receptors undergo a different pattern of agonistinduced internalization compared with extrasynaptic DA receptors [3] . Considering the unique structure of postsynaptic density (PSD) and its role in the modulation of neurotransmission [4] , it is reasonable to speculate that the PSD may play an important role in functional regulation of the DA receptor.
The PSD is enriched with PSD-95 protein.
It is now clear that the PSD-95 family of proteins not only act as anchor proteins, but also function as important modulators of signaling [4, 5] . Abnormal PSD-95 expression has been implicated in Parkinson's disease and schizophrenia and is believed to contribute to abnormal neurotransmission in these diseases [6] [7] [8] . The direct association of PSD-95 with N-methyl-D-aspartate (NMDA) or other receptors was demonstrated to be an essential mechanism for PSD-95-regulated function of those neurotransmitter receptors [9] [10] [11] . In addition, PSD-95 associates with adhesion molecules, signaling enzymes and ion channels [12] [13] [14] [15] [16] . We recently reported that modulation of NMDA receptor function by D 1 receptor requires the presence of PSD-95. In the absence of PSD-95, D 1 receptors fail to regulate NMDA receptor function. We further demonstrated that PSD-95 physically associates with the D 1 DA receptor [17] . A recent report also confirmed this association [18] . The present investigation aims to clarify the functional relationship between PSD-95 and D 1 , as well as other DA receptors. Specifically, we examined the role of PSD-95 in D 1 receptor function and trafficking. Our results reveal a dynamic association of PSD-95 with the D 1 receptor in response to DA receptor stimulation. We demonstrated that this association did not alter D 1 receptor-stimulated cAMP production or Gs-protein activation, but significantly enhanced the resensitization of the D 1 DA receptor by accelerating D 1 receptor recycling to the cell membrane. The present study provides a novel mechanism for regulating DA receptor recycling that may play an important role in postsynaptic DA functional modulation and synaptic neuroplasticity.
Results

Both D 1 and D 2 DA receptors are physically associated with PSD-95
In HEK-293 cells co-expressing D 1 (HA-tagged) and PSD-95 (myc-tagged), PSD-95 was found in the D 1 is known to dimerize [19] , we used cells co-expressing D 1 -CFP and D 1 -YFP as positive controls. FRET signals (3.64 ± 0.37%, n = 45) similar to those between D 1 and PSD-95 were observed, whereas no FRET signal was detected (FRET efficiencies of 0.02 ± 0.78%, n = 25) from negative control cells in which D 1 -CFP was co-expressed with the unrelated TRPV3 channel (TRPV3-YFP). Moreover, when the same FRET method was applied to cells expressing D 1 -CFP alone, a FRET value of less than 0.01% was obtained, further confirming the reliability of the approach. In agreement with a previous report [18] , we also demonstrated that all NT-containing domains of PSD-95 are able to support the interaction between D 1 receptor and PSD-95, regardless of truncations ( Figure  1D ). Taken together, our data suggest that the D 1 receptor associates directly with PSD-95. Remarkably, the direct interaction was not limited to the D 1 receptor and PSD-95 because we also found constitutive interactions between PSD-95 and the D 2 and D 5 DA receptors ( Figure 1E ). These data therefore indicate that PSD-95 interacts with both D 1 -like and D 2 DA receptors.
Stimulation of D 1 receptors alters the interaction between D 1 receptor and PSD-95 in vitro and in vivo
To determine whether interaction between D 1 receptor and PSD-95 can be regulated by receptor activation, HEK-293 cells were transiently transfected with D 1 -CFP and PSD-95-YFP. FRET signals were determined before and after DA treatment (10 µM). There was a significant increase in FRET signal (from 2.96 ± 0.49% to 6.87 ± 1.16%; P < 0.0005) after 5 min of treatment with DA ( Figure 2A) . The results are consistent with the co-immunoprecipitation data. However, the enhanced association in response to D 1 receptor stimulation was transient because it rapidly returned to basal levels after 30 min ( Figure 2B ). This transient alteration of association was also observed in vivo. Administration of the D 1 receptor agonist, SKF38393 (i.p., 2 mg/kg), to rats significantly enhanced frontal cortical D 1 receptor-PSD-95 association measured at 8 min (2.07-fold, P < 0.01) and 16 min (1.64-fold, P < 0.05) ( Figure 2C ). This result indicates that D 1 receptor activation increases the association of brain D 1 receptor and PSD-95 in vivo.
PSD-95 does not alter D 1 receptor-stimulated cAMP production
We next studied whether the association between D 1 and PSD-95 alters D 1 receptor-stimulated cAMP production in response to DA stimulation. HEK-293 cells stably expressing D 1 receptors were transiently transfected with mock, full-length or truncated PSD-95; DA-stimulated cAMP accumulation was assessed. No significant stimulation of cyclase was detected with the full-length or truncated forms of PSD-95 ( Figure 3A and Figure 3B ). This is further supported by the data obtained from saturation-binding analyses in which co-transfection of PSD-95 elicited no effect on membrane D 1 receptor-binding properties (K d , 1.31 ± 0.16 vs 1.39 ± 0.18 nM; B max , 10.67 ± 1.14 vs 10.59 ± 2.30 pmol/mg) ( Figure 3C ). Taken together, our data clearly indicate that PSD-95 does not alter D 1 receptor activation.
PSD-95 does not alter D 1 receptor desensitization, but enhances D 1 receptor resensitization
The results described in the above section indicate that PSD-95 does not affect D 1 receptor-stimulated cAMP npg production; we wondered whether PSD-95 alters receptor desensitization and/or resensitization. Desensitization was assessed in HEK-293 cells stably expressing D 1 that were transiently co-transfected with mock, full-length or truncated PSD-95. The cells were treated with DA and washed prior to being challenged with DA for an additional 10 min to assess receptor desensitization. The cells were then harvested for cAMP assay. As shown in Figure 4 , DA-stimulated cAMP production was not changed by either PSD-95 or its truncated forms, clearly indicating that PSD-95 elicits no effect on D 1 receptor desensitization.
To assess resensitization, stable D 1 -expressing HEK-293 cells were transiently co-transfected with mock, fulllength ( Figure 5A The prefrontal cortex was then collected and lysed. D 1 receptor immunoprecipitation was performed as described using anti-D 1 DR antibody; for Western blot anti-PSD-95 antibody (1:1 000) was used. Data are representative results from at least three independent experiments for (B and C). Quantification of PSD-95 levels (shown in the bar graphs) was performed as described under Materials and Methods. **P < 0.01, *P < 0.05.
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). Cells were pre-incubated with 10 µM DA for 1 h to induce receptor desensitization. The cells were washed three times and challenged at the designated times with DA for 10 min before measurement of cAMP. Figure 5A indicates that PSD-95 significantly enhanced D 1 receptor resensitization. A significant enhancement was already observed at 3 h (P < 0.05) following the initial 1-h DA treatment, and this enhancement increased further at subsequent time points (5 h, P < 0.01) compared with cells that were not co-transfected with PSD-95 ( Figure 5A ).
However, it was also noted that co-transfection with the PSD mutants failed to induce a change in D 1 receptor resensitization ( Figure 5B ). Thus, it appears that full-length PSD-95 is required for D 1 receptor resensitization.
PSD-95 accelerates membrane D 1 receptor recovery via enhancement of receptor recycling
To find out how PSD-95 enhances D 1 receptor resensitization, we examined the recovery of plasma membrane D 1 receptors. In this experiment, cells were subjected npg to DA stimulation for 1 h to induce D 1 receptor internalization. The cells were then washed and cultured for 2, 6 or 15 h before cell collection and measurement of cell surface D 1 receptors was performed using the method described above. The density of cell surface D 1 receptors was reduced to 61.68 ± 9.06% in D 1 receptorexpressing cells and to 60.26 ± 12.36% in D 1 and PSD-95 co-expressing cells in response to 1-h DA stimulation compared with the respective control cells that were not exposed to DA. At 2 h after washing, D 1 DA receptor density in the plasma membranes of D 1 /PSD-95 coexpressing cells was significantly higher than that of cells expressing D 1 and mock (76.45 ± 7.21% vs 63.47 ± 9.88%). At 6 h after washing, the membrane receptors recovered to 98.49 ± 13.66% of control in D 1 /PSD-95 coexpressing cells, which is significantly higher than that observed in membranes taken from cells without PSD-95 co-expression (53.15 ±19.61%). There was only 77.78 ± 4.91% recovery of D 1 receptors at the cell surface in D 1 -expressing cells at 15 h after washing, whereas the full recovery of membrane D 1 receptors was achieved at 6 h in the presence of PSD-95 ( Figure 6A ). This membrane receptor recovery pattern is in agreement with the results of D 1 receptor resensitization (Figure 5A ). This indicates that PSD-95 shortens the time necessary for internalized D 1 receptors to return to the membrane. This conclusion is in agreement with the enhanced membrane D 1 receptor signals observed by con- Figure 6B . Data are presented as means ± SE from at least 20 cells for each condition. ***P < 0.0001 compared with the DA 1-h group using Student's paired t-test. DA receptors play critical roles in many aspects of brain function; abnormal dopaminergic activity is closely associated with Parkinson's disease, schizophrenia, drug addiction and other neurological and psychiatric disorders [20, 21] . Like other G-protein-coupled receptors, the DA receptors are subject to internalization, desensitization and resensitization in response to agonist stimulation [1, 2] . Modulation of DA receptor trafficking has become a focal point in attempts to understand the receptor's functional regulation. Anatomically, the D 1 DA receptors are localized in both perisynaptic and extrasynaptic areas. The present data demonstrate that the association of PSD-95 with the D 1 DA receptor is involved in D 1 receptor trafficking and consequently results in an acceleration in D 1 DA receptor resensitization. The postsynaptic area is enriched with PSD-95 [22] ; PSD-95-accelerated D 1 receptor recycling and resensitization may represent a potential mechanism for the regulation of postsynaptic membrane D 1 receptors in response to the pulse release of DA from nerve terminals. Our data suggest that PSD-95 accelerates D 1 receptor recycling back to the plasma membrane, thus shortening the time of receptor recovery following receptor stimulation and subsequent internalization (Figures 6 and 7) . It is thought that receptor endocytosis of desensitized GPCR is an initial step in the resensitization process that requires ligand-receptor dissociation and receptor dephosphorylation [23, 24] . Subsequently, the receptor may recycle to the membrane or be targeted for degradation [24, 25] . The recovery of receptors at the membrane has been attributed to the synthesis and insertion of more receptors, as well as to the PSD-95 regulates dopamine receptor resensitization 620 npg recycling of endocytosed receptors [25] . We found that co-transfection with PSD-95 did not alter D 1 DA receptor expression ( Figure 3C ), and protein synthesis inhibition did not affect PSD-95-promoted D 1 receptor recycling ( Figure 7A ). This suggests that PSD-95-accelerated D 1 receptor recovery is independent of new receptor synthesis. In contrast, monensin, which inhibits the recycling pathway, prevented the accelerated recovery of membrane D 1 receptors (Figure 7B ), indicating that receptor recycling is the predominant mechanism involved in the PSD-95-accelerated recovery of membrane D 1 DA receptors following desensitization/internalization.
Although the underlying mechanism for PSD-95-stimulated recycling is presently unknown, it is clear that full-length PSD-95 is necessary and sufficient for accelerating D 1 DA receptor recycling. None of the truncated PSD-95 constructs, when co-expressed with the D 1 DA receptor, affected receptor resensitization ( Figure 5B ). Interestingly, whereas the D 1 receptor associated with PSD-95ΔSH3&GK and PSD-95ΔGK, these constructs did not affect receptor resensitization. This indicates that although physical interaction is mediated through the N-terminus, PSD-mediated resensitization requires fulllength PSD-95.
A recent study has shown that PSD-95 inhibits D 1 receptor-stimulated cAMP production in HEK-293 cells co-transfected with monkey D 1 receptor and PSD-95 [18] . In contrast, we did not detect a significant change in D 1 receptor-stimulated cAMP content ( Figure 3A and Table 1 ). Our observation is supported by results of the receptor-activated [ 35 S]GTPγS binding assay that directly assesses receptor-mediated Gs-protein activation. In this experiment, we did not find any evidence for a PSD-95-induced change in receptor-mediated Gs-protein activation in cells co-transfected with PSD-95 and D 1 receptors ( Figure 3B ). In fact, in some experiments we noted a slight increase in cellular cAMP production after D 1 receptor stimulation. The reason for these contradictory results is currently unknown. However, the two studies differ in the agonists used (DA/SKF38393 vs SKF81297) and receptor clones (human vs rhesus monkey D 1 ). These differences could underlie the discrepancy in results between the two studies. D 1 receptor desensitization in response to agonist stimulation is believed to be associated with receptor phosphorylation, which, consequently, results in uncoupling of the D 1 DA receptor from its cognate G-protein and reduction of receptor activity [26] . Unlike a previous report showing that PSD-95 alters NMDA receptor desensitization [27] , our present data demonstrate that PSD-95 elicited no change in D 1 DA receptor desensitization (Figure 4) , suggesting that PSD-95 may not alter agonist-induced D 1 receptor phosphorylation.
PSD-95 is enriched in the postsynaptic area; alterations in PSD-95 were found in a number of neuropsychiatric and neurological diseases such as Alzheimer's disease, schizophrenia and Parkinson's disease. The changes in PSD-95 were suggested to be associated with altered synaptic functions [7, 8, 28, 29] . The D 1 receptor co-localizes with the NMDA receptor [30, 31] in which this interaction is critical for the formation of NMDAmediated long-term potentiation [32, 33] . PSD-95 modulates NMDA excitatory synaptic function by directly interacting with NR2A or NR2B subunits of the NMDA receptor [34] [35] [36] . We recently reported that D 1 receptor modulation of NMDA receptor function depends on the presence of PSD-95, indicating that PSD-95 acts as an intermediate in D 1 receptor-regulated NMDA function. PSD-95 may, in turn, alter synaptic function and neuroplasticity [17] . In schizophrenia and in affective disorders, hypoactivity of NMDA receptor function and abnormal dopaminergic activity are believed to underlie the pathophysiological mechanisms. Decreased PSD-95 expression in schizophrenia has been reproducibly observed [6, 7] . It would be of great interest to study how altered PSD-95 affects the DA and NMDA receptor interaction that may ultimately result in the disruption of the neurotransmission balance in schizophrenia.
Finally, it is interesting to note that activation of the D 1 receptor resulted in a transient increase in the association between D 1 and PSD-95 both in vitro and in vivo ( Figure  2B and 2C ). This is of interest because it may indicate that the agonist-modulated conformation of D 1 receptor could make the receptor more accessible for PSD-95 binding. The mechanism underlying altered PSD-95 and D 1 association, as well as the pursuant functional implications is currently being studied in our laboratory. receptor-expressing stable cell lines, G418 (Sigma) was added at the concentration of 300 µg/ ml and was maintained at 100 µg/ml. In all experiments in which DA was applied, 100 µM L-ascorbic acid was included.
Materials and Methods
Materials
Preparations of cDNA constructs
The cDNA construct for PSD-95 was from Dr Morgan Sheng (Harvard University, Boston, MA, USA). All PSD-95 and mutant PSD-95 constructs used contained a c-Myc epitope tag inserted between residues 9 and 10 of PSD-95. Because a recent report indicated that the N terminus of PSD-95 is necessary for its association with D 1 receptor [18] , all constructs made contained this N terminus. PSD-95ΔSH3&GK, PSD-95ΔGK, PSD-95ΔPDZ123 and PSD-95 cDNA-encoding fragments (as depicted by the figure depicting constructs used) were amplified by PCR from full-length cDNA clones. PSD-95, PSD-95ΔSH3&GK and PSD-95ΔGK were subcloned into pcDNA 3.0 using the KpnI and EcoRI restriction sites. PSD-95ΔPDZ123 was subcloned into pcDNA 3.0 PSD-95-NT using the EcoRI and XhoI restriction sites. Initiation methionine residues and stop codons were also incorporated where appropriate. YFP-tagged PSD 
Spectral fluorescence resonance energy transfer (spectral FRET) measurements
FRET signals were determined as previously described [37] . HEK-293 cells were transiently transfected with D 1 receptor in pECFP-N1 vector (D 1 -CFP) and PSD-95 in pEYFP-N1 vector (PSD-95-YFP) using Lipofectamine TM 2000 (GIBCO BRL) according to the procedure recommended by the manufacturer. Fluorescence imaging was performed at room temperature 1-2 days after transfection. Immediately before fluorescence recording, the culture medium was replaced with a solution containing 130 mM NaCl, 5 mM MgCl 2 , 2 mM CaCl 2 , 5 mM HEPES and 1 mM EGTA (pH 7.4). Epifluorescence microscopy was carried out with a fully automated, inverted fluorescence microscope (Olympus IX-81) controlled by MetaMorph software (Universal Imaging, Inc.). Two filter sets (Chroma) were used: for CFP and FRET imaging, the filter set contained a D436/20 excitation filter and a 455dclp dichroic mirror; for YFP imaging, the filter set contained an HQ500/20 excitation filter and a Q515lp dichroic mirror. Fluorescence emission was detected with an HQ CCD camera (Hamamasu). For spectroscopic imaging, a spectrograph (Acton SpectraPro 2150i) was used in conjunction with the camera. Emission spectra specifically from the plasma membrane of the cell were collected by positioning the spectrograph slit across a cell and recording the fluorescence intensity at the position corresponding to the membrane region; the same slit position applied to both the spectrum taken with CFP excitation and the spectrum taken with YFP excitation. FRET efficiency was calculated as the enhanced YFP emission resulting from energy transfer, using an approach that was previously described [38] .
Immunoprecipitation (IP) and immunoblot (IB) assay
Transfected HEK-293 cells were collected and lysed in a lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA and 1% Triton X-100, pH 7.4) containing a protease inhibitor cocktail (Sigma), incubated on ice for 30 min and centrifuged at 5 000 × g for 10 min. The prefrontal cortex tissues were homogenized in buffer (20 mM HEPES, 150 mM NaCl, 2 mM EDTA, 10% glycerol and 0.5% NP-40, pH 7.4) and protease inhibitor cocktail, incubated on ice for 30 min and centrifuged at 20 000 × g for 10 min. The protein contents of the supernatants from HEK-293 cells and brain tissues were determined by bicinchoninic acid (BCA) protein assay. Aliquots of the lysate were used to detect the total expression of PSD-95 and the remainder was used for immunoprecipitation.
Aliquots of supernatant (500 µg for cells or 800 µg for tissues) were immunoprecipitated with 1 µg anti-HA (for cells expressing D 1 , D 2 and D 5 receptor) or anti-D 1 receptor (for tissues) at 4°C overnight with gentle rotation, followed by the addition of agarose-conjugated protein A/G PLUS beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for an additional 1 h at 4 °C. To exclude the potential nonspecific pull-down, controls were included: the same amount of sample protein immunoprecipitated with non-immuno IgG; omission of the sample protein during immunoprecipitation or omission of the appropriate antibody during immunoprecipitation. The immunocomplex was then collected by centrifugation and, after samples were washed five times, the pellets were boiled in sample preparation buffer for the immunoblot assay. The immunoprecipitates or lysates were loaded onto SDS-PAGE. The proteins were separated electrophoretically and transferred to PVDF membranes (Bio-Rad). The membranes were blocked with 10% (w/v) fat-free dry milk in 0.1% Tween 20-TBS (TBST) for 2 h, followed by incubation with antibody overnight at 4 °C. The membranes were washed three times with TBST and then incubated for 1 h with species-specific HRP-conjugated secondary IgG antibody (1:5 000-1:10 000 dilution; Santa Cruz) at room temperature. The membranes were washed three times for 5 min with TBST and the signals were visualized by the ECL/HRP method (Supersignal, Pierce). The band density of D 1 receptorassociated PSD-95 was quantified by densitometry and expressed as the fold change over vehicle control.
Crude membrane preparation
Transfected HEK-293 cells were grown to confluence, washed twice with ice-cold phosphate-buffered saline (PBS), harvested with PBS and collected through centrifugation at 100 × g for 10 min. The cells were then lysed in hypotonic buffer (5 mM TrisHCl and 2 mM EDTA, pH 7.4), containing a protease inhibitor mixture (Sigma) and sonicated three times for 18 s. The lysate was centrifuged at 100 × g for 10 min; the supernatant was further centrifuged at 40 000 × g for 30 min at 4 °C; the pellet was resuspended in binding buffer (50 mM Tris-HCl, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl 2 , 4 mM MgCl 2 and 120 mM NaCl, pH 7.4) for npg receptor-binding assays. The protein content of membranes was determined by the BCA method.
Radioligand binding assays
For radioligand saturation binding assays, the crude membrane preparation (3 µg/tube) was added to assay tubes containing 0.1 to 10 nM [ 3 H]SCH23390 in a total volume of 0.2 ml. (+)-Butaclamol was added at the final concentration of 1 µM to determine nonspecific binding. After 60 min of incubation at 30 °C, the reaction was terminated by rapid filtration through a 24-well cell harvester (Brandel, Montreal, Canada) onto Whatman GF/B filters. Filters were washed with 4 ml of ice-cold washing buffer (50 mM TrisHCl and 2 mM EDTA, pH 7.4) three times. Radioactivity bound to the filters was quantified using a Beckman LS 6500 scintillation counter. All experiments were performed in duplicate, and each experiment was repeated at least three times.
Assays of cAMP content
After 24-h transfection of plasmid-encoding D 1 receptor with mock, full-length or truncated PSD-95, cells were reseeded into 96-well plates (1 × 10 4 cells/well). For the assay of cAMP accumulation, cells were preincubated with 100 µl of serum-free DMEM containing 500 µM IBMX (Sigma) prior to the addition of DA at various concentrations. For receptor desensitization experiments, cells were pretreated with 10 µM DA for the indicated time and washed with serum-free DMEM before DA challenge. For receptor resensitization experiments, cells were pre-incubated with 10 µM DA for 1 h and washed, and then cells were incubated in serum-free DMEM for the indicated time before DA challenge. The reaction was then terminated on ice by the addition of 100 µl of 1 M trichloroacetic acid, followed by the addition of 20 µl 2 M K 2 CO 3 . The samples were centrifuged for 10 min at 3 000 × g. The supernatants were kept (diluted 1:50) for determining cAMP content using the [ 125 I] cAMP assay kit. All experiments were performed in duplicate and each experiment was repeated at least three times. 35 S]GTPγS and 20 µM GDP (Sigma) in the absence or presence of various concentrations of DA. The reaction was stopped after 10 min of incubation at 30 °C with 3 ml of ice-cold reaction buffer. Samples were filtered rapidly through a GF/B filter and rinsed three times with 3 ml of reaction buffer. Filters were dried and the binding activity was measured by liquid scintillation counting. Nonspecific binding was detected in the presence of 100 µM unlabeled GTPγS (Sigma).
Measurement of cell surface receptors
Crude cell membranes were prepared as described above. The heavy membrane fraction and the light vesicular membrane were separated using a method described by Lamey et al. [39] . Briefly, crude membranes were resuspended in hypotonic buffer (5 mM Tris-HCl and 2 mM EDTA, pH 7.4) with protease inhibitor mixture, layered on top of a 35% sucrose cushion, and then centrifuged at 150 000 × g for 90 min at 4 °C. The heavy membrane fractions at the bottom of the sucrose cushion were resuspended in binding buffer and the protein contents were determined by the BCA method and adjusted (10 µg/tube) for radioligand binding assays using 1.2 nM [ 
Confocal microscopy and image quantification
Cells expressing D 1 -CFP with or without co-expression of PSD-95-YFP were treated either with 10 µM DA or vehicle for the indicated time in serum-free DMEM and then washed three times with ice-cold PBS to stop the reaction. For assays of cell surface receptor recovery, cells were rinsed once with PBS and then incubated in serum-free DMEM for 2 or 6 h followed by treatment with 10 µM DA or vehicle for 1 h. The cells were then fixed in 4% paraformaldehyde for 20 min at room temperature prior to three washes with PBS. Recovery of the receptor was then observed with a Leica SP2 confocal microscope. For quantifying the ratio of cell-surface D 1 receptor signal to whole-cell D 1 receptor signal, the D 1 receptor fluorescence intensities for whole cell and for intracellular signal were measured for each cell. The ratio of cell surface D 1 receptors was defined as (1 − intracellular/total cellular fluorescence) × 100%.
Data analysis
The radioligand binding parameters K d and B max , as well as the EC 50 and E max values for DA-stimulated cAMP production were fitted and calculated using the Prism program (GraphPad Software, San Diego, CA, USA). The curves presented in this paper represent the best fits to the data. Data were expressed as the means ± SE. Significance was considered at the P < 0.05 level using Student's paired t-test or one-way ANOVA. Semi-quantification of immunoblot signals was performed by scanning the films and analysis was performed using NIH Image software.
